Phyteau
Phyteau is a biotech spin-out from Cedars-Sinai Medical Center, CALTECH, and UCLA, focused on developing safe and effective therapeutics for diabetes, obesity, and metabolic conditions. Their innovative approach leverages a new class of incretin-based therapy to improve health outcomes at a lower cost, aiming to reverse metabolic diseases and improve quality of life.
Industries
Nr. of Employees
small (1-50)
Phyteau
Products
Oral incretin-based therapeutic (weight loss and diabetes pill)
An orally administered therapeutic candidate designed to activate enteroendocrine hormone release to reduce postprandial glucose peaks and increase satiety while limiting systemic exposure.
Phyteau
Phyteau is a powerful weight loss and diabetes pill which drives better outcomes at a lower cost compared to current injectable, GLP-1 products. It activates the body’s metabolic hormone system to release therapeutic levels of key hormones, including GLP-1, PYY, OXM and CCK, to improve blood sugar processing, reduce blood sugar peaks after meals and increase satiety. The therapeutics work inside the gut and are designed to restrict systemic exposure producing an exceptional safety profile.
Oral incretin-based therapeutic (weight loss and diabetes pill)
An orally administered therapeutic candidate designed to activate enteroendocrine hormone release to reduce postprandial glucose peaks and increase satiety while limiting systemic exposure.
Phyteau
Phyteau is a powerful weight loss and diabetes pill which drives better outcomes at a lower cost compared to current injectable, GLP-1 products. It activates the body’s metabolic hormone system to release therapeutic levels of key hormones, including GLP-1, PYY, OXM and CCK, to improve blood sugar processing, reduce blood sugar peaks after meals and increase satiety. The therapeutics work inside the gut and are designed to restrict systemic exposure producing an exceptional safety profile.
Expertise Areas
- Metabolic disease therapeutics
- Incretin and enteroendocrine biology
- Oral drug delivery for gut-restricted action
- Translational research from academia to therapeutics
Key Technologies
- Enteroendocrine modulation
- Incretin-based therapeutic platforms
- Gut-restricted oral delivery
- Hormone release modulation (GLP-1, PYY, OXM, CCK)